GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35
Multiple sclerosis (MS) still lacks reliable biomarkers of neuroinflammation predictive for disease activity and treatment response. Thus, in a prospective study we assessed 55 MS patients (28 interferon (IFN)-treated, 10 treated with no-IFN therapies, 17 untreated) and 20 matched healthy controls (...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/14/11/1195 |
| _version_ | 1797508824306810880 |
|---|---|
| author | Roberto De Masi Stefania Orlando |
| author_facet | Roberto De Masi Stefania Orlando |
| author_sort | Roberto De Masi |
| collection | DOAJ |
| description | Multiple sclerosis (MS) still lacks reliable biomarkers of neuroinflammation predictive for disease activity and treatment response. Thus, in a prospective study we assessed 55 MS patients (28 interferon (IFN)-treated, 10 treated with no-IFN therapies, 17 untreated) and 20 matched healthy controls (HCs) for the putative correlation of the densitometric expression of glucosidase II alpha subunit (GANAB) with clinical/paraclinical parameters and with interferon-induced protein 35 (IFI35). We also assessed the disease progression in terms of the Rio Score (RS) in order to distinguish the responder patients to IFN therapy (RS = 0) from the non-responder ones (RS ≥ 1). We found GANAB to be 2.51-fold downregulated in the IFN-treated group with respect to the untreated one (<i>p</i> < 0.0001) and 3.39-fold downregulated in responder patients compared to the non-responders (<i>p</i> < 0.0001). GANAB correlated directly with RS (r = 0.8088, <i>p</i> < 0.0001) and lesion load (LL) (r = 0.5824, <i>p</i> = 0.0014) in the IFN-treated group and inversely with disease duration (DD) (r = −0.6081, <i>p</i> = 0.0096) in the untreated one. Lower mean values were expressed for GANAB than IFI35 in IFN responder (<i>p</i> < 0.0001) and higher mean values in the non-responder patients (<i>p</i> = 0.0022). Inverse correlations were also expressed with IFI35 in the overall patient population (r = −0.6468, <i>p</i> < 0.0001). In conclusion, the modular expression of GANAB reflects IFI35, RS, DD, and LL values, making it a biomarker of neuroinflammation that is predictive for disease activity and treatment response in MS. |
| first_indexed | 2024-03-10T05:10:21Z |
| format | Article |
| id | doaj.art-cf5ad9c582db4e58845a5c6cfa3c41cd |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T05:10:21Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-cf5ad9c582db4e58845a5c6cfa3c41cd2023-11-23T00:56:42ZengMDPI AGPharmaceuticals1424-82472021-11-011411119510.3390/ph14111195GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35Roberto De Masi0Stefania Orlando1Complex Operative Unit of Neurology, “F. Ferrari” Hospital, Casarano, 73042 Lecce, ItalyLaboratory of Neuroproteomics, Multiple Sclerosis Centre, “F. Ferrari” Hospital, Casarano, 73042 Lecce, ItalyMultiple sclerosis (MS) still lacks reliable biomarkers of neuroinflammation predictive for disease activity and treatment response. Thus, in a prospective study we assessed 55 MS patients (28 interferon (IFN)-treated, 10 treated with no-IFN therapies, 17 untreated) and 20 matched healthy controls (HCs) for the putative correlation of the densitometric expression of glucosidase II alpha subunit (GANAB) with clinical/paraclinical parameters and with interferon-induced protein 35 (IFI35). We also assessed the disease progression in terms of the Rio Score (RS) in order to distinguish the responder patients to IFN therapy (RS = 0) from the non-responder ones (RS ≥ 1). We found GANAB to be 2.51-fold downregulated in the IFN-treated group with respect to the untreated one (<i>p</i> < 0.0001) and 3.39-fold downregulated in responder patients compared to the non-responders (<i>p</i> < 0.0001). GANAB correlated directly with RS (r = 0.8088, <i>p</i> < 0.0001) and lesion load (LL) (r = 0.5824, <i>p</i> = 0.0014) in the IFN-treated group and inversely with disease duration (DD) (r = −0.6081, <i>p</i> = 0.0096) in the untreated one. Lower mean values were expressed for GANAB than IFI35 in IFN responder (<i>p</i> < 0.0001) and higher mean values in the non-responder patients (<i>p</i> = 0.0022). Inverse correlations were also expressed with IFI35 in the overall patient population (r = −0.6468, <i>p</i> < 0.0001). In conclusion, the modular expression of GANAB reflects IFI35, RS, DD, and LL values, making it a biomarker of neuroinflammation that is predictive for disease activity and treatment response in MS.https://www.mdpi.com/1424-8247/14/11/1195GANABIFI35neuroinflammationmultiple sclerosisinterferon |
| spellingShingle | Roberto De Masi Stefania Orlando GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35 Pharmaceuticals GANAB IFI35 neuroinflammation multiple sclerosis interferon |
| title | GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35 |
| title_full | GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35 |
| title_fullStr | GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35 |
| title_full_unstemmed | GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35 |
| title_short | GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35 |
| title_sort | ganab as a novel biomarker in multiple sclerosis correlation with neuroinflammation and ifi35 |
| topic | GANAB IFI35 neuroinflammation multiple sclerosis interferon |
| url | https://www.mdpi.com/1424-8247/14/11/1195 |
| work_keys_str_mv | AT robertodemasi ganabasanovelbiomarkerinmultiplesclerosiscorrelationwithneuroinflammationandifi35 AT stefaniaorlando ganabasanovelbiomarkerinmultiplesclerosiscorrelationwithneuroinflammationandifi35 |